tibulizumab

Tibulizumab is a tetravalent bispecific humanized monoclonal antibody that simultaneously targets and neutralizes two key cytokines involved in autoimmune disease pathogenesis: interleukin 17A (IL-17A) and B cell activating factor (BAFF). It was engineered by fusing the antigen-binding domains of Taltz (ixekizumab, an anti–IL-17A antibody) and tabalumab (an anti–BAFF antibody), resulting in a molecule capable of independently antagonizing both targets. Tibulizumab disrupts both T-cell–driven inflammation via IL-17A inhibition and B-cell survival/autoantibody production via BAFF inhibition. This dual mechanism aims to address diseases with overlapping T-cell and B-cell mediated pathology. The drug has demonstrated acceptable safety in early clinical trials for rheumatoid arthritis and Sjögren’s syndrome, with ongoing development for systemic sclerosis (systemic scleroderma) and planned studies in hidradenitis suppurativa[1][3][4][5][6][7].

Other names

Anti-BAFF IL-17A monoclonal antibodyBAFF/IL-17A-Eli-Lilly and Company